Dilated Cardiomyopathy
Dilated Cardiomyopathy - Related Videos
01:30
Cardiomyopathy II: Dilated Cardiomyopathy
0 Views •
2025
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
0 Views •
Cited by 7 •
2020
Described is a protocol to establish a Doxorubicin-induced dilated cardiomyopathy (DCM) model in mice via long-term intraperitoneal injection of Doxorubicin.
01:29
Cardiomyopathy IV: Restrictive Cardiomyopathy
0 Views •
2025
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:29
Cardiomyopathy III: Hypertrophic Cardiomyopathy
0 Views •
2025
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
04:47
Zebrafish Cardiomyopathy Model: Drug-Induced Cardiotoxicity
0 Views •
2023
This video describes the technique of creating a zebrafish cardiomyopathy model with minimal variations among experimental groups and in the sample, we create zebrafish cardiomyopathy model using the drug doxorubicin.
FAQs
Ventricular remodeling can enlarge one or both ventricles while altering the structure of cardiac muscle. These changes reduce the effectiveness of contraction, so the heart pumps blood less efficiently. Studying remodeling helps connect cellular injury or weakness with organ-level decline and clarifies why preserving muscle performance is important for limiting progression toward heart failure.
Genetic factors, infections, toxins, and other conditions are identified as possible contributors. Although these causes differ, each can produce structural changes in cardiac muscle that weaken contraction. Examining these different origins allows biology and medicine researchers to investigate how distinct initiating factors converge on impaired heart function and ventricular enlargement.
Reduced ventricular contraction can interfere with effective blood movement through the heart, promoting blood-flow congestion. Structural changes in cardiac muscle can also disturb the heart’s electrical behavior, creating abnormal rhythms. These consequences show that the disorder affects both mechanical pumping and electrical coordination, rather than contraction alone.
When cardiac muscle contracts less effectively, the heart’s ability to pump blood declines and structural changes may continue. Research therefore focuses on therapies that preserve muscle performance and prevent progression toward heart failure. This goal links cellular investigations with clinically important outcomes, including maintaining organ function and reducing the effects of remodeling.
Diagnosis and investigation help characterize the structural and functional changes associated with the disorder. They support risk assessment by identifying the significance of weakened contraction, ventricular remodeling, congestion, and abnormal electrical rhythms. In research and medicine, this information also provides a basis for evaluating treatments intended to preserve cardiac performance and limit progression.
The condition provides a model for tracing how changes in cardiac muscle cells can produce enlargement of the ventricles, weaker contraction, impaired blood pumping, congestion, and abnormal rhythms. This cellular-to-organ perspective is important in biology because it connects underlying mechanisms with measurable cardiac outcomes and guides research into therapies that protect heart muscle.